Radiochemistry Core

放射化学核心

• 批准号: 10251320
• 负责人: Suzanne Elizabeth Lapi
• 金额: $ 12.78万
• 依托单位: PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-08 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10251320
• 关键词: Affinity; Animal Model; Annexin A1; Antibodies; Biodistribution; Caveolae; Clinical Research; Clinical Trials; Complement; Cyclic GMP; Cyclotrons; Development; Disease; Doctor of Philosophy; Drug Kinetics; Goals; Human; Image; Label; Lesion; Patients; Production; Pump; Quality Control; Radiochemistry; Radioimmunoconjugate; Radioisotopes; Radiolabeled; Radiology Specialty; Radionuclide Imaging; Radiopharmaceuticals; Solid Neoplasm; Specificity; System; Testing; Therapeutic Agents; Translations; base; cGMP production; chemoradiation; clinical imaging; experimental study; first-in-human; imaging agent; imaging modality; imaging study; improved; insight; mid-career faculty; molecular imaging; novel; pre-clinical; preclinical imaging; radiotracer

CORE D PROJECT SUMMARY This Core will enable key insights into the pharmacokinetics and biodistribution of the humanized form of our Annexin A1 targeting antibody (hAnnA1) by providing 89Zr-hAnnA1 for imaging studies in both preclinical and a first-in-human clinical trial. The goal of the Core D Radiochemistry Core is to radiolabel antibodies for use in Projects 1 and 3. Core D will also conduct the pilot imaging study with 89Zr-hAnnA1 that is prepared by the Core under cGMP conditions. Imaging with hAnnA1-based targeting is promising due to high target affinity and specificity which leads to reduced off target effects. When hAnnA1 is conjugated to radionuclides for imaging, new radiopharmaceuticals can be developed which are complementary to more conventional imaging modalities. The Core will enable the caveolae pumping system to be evaluated for its ability to deliver precisely antibodies labeled with radionuclides directly into solid tumors and metastastic lesions. Core D will produce radiotracers essential to the aims in Projects 1 and 3, and will be instrumental in the development of novel precision delivered radiopharmaceuticals to image and treat metastatic disease in humans.

核心D项目总结 该核心将使我们的人源化形式的药代动力学和生物分布的关键见解 膜联蛋白A1靶向抗体（hAnnA 1）通过提供89 Zr-hAnnA 1用于临床前和临床试验中的成像研究 首次人体临床试验核心D放射化学核心的目标是放射性标记抗体，用于 项目1和3。核心D还将使用核心D制备的89 Zr-hAnnA 1进行初步成像研究。 在cGMP条件下。基于hAnnA 1的靶向成像是有希望的，因为其具有高靶亲和力， 特异性，导致脱靶效应降低。当hAnnA 1与放射性核素结合用于成像时， 可以开发新的放射性药物，其补充更常规的成像模式。 核心将使小窝泵送系统能够评估其精确输送抗体的能力 用放射性核素直接标记到实体瘤和恶性病变中。 核心D将生产对项目1和3的目标至关重要的放射性示踪剂，并将有助于 开发新的精确递送的放射性药物以成像和治疗人类转移性疾病。